Compare TGLS & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGLS | ODTX |
|---|---|---|
| Founded | 1984 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2011 | 2025 |
| Metric | TGLS | ODTX |
|---|---|---|
| Price | $42.27 | $18.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $55.75 | $35.33 |
| AVG Volume (30 Days) | ★ 339.1K | 254.7K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $370,984,000.00 | N/A |
| Revenue This Year | $12.84 | N/A |
| Revenue Next Year | $11.44 | N/A |
| P/E Ratio | $33.71 | ★ N/A |
| Revenue Growth | ★ 17.98 | N/A |
| 52 Week Low | $34.05 | $15.10 |
| 52 Week High | $54.85 | $29.05 |
| Indicator | TGLS | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 70.06 | 48.46 |
| Support Level | $42.49 | $19.31 |
| Resistance Level | $47.87 | $19.60 |
| Average True Range (ATR) | 1.37 | 1.68 |
| MACD | 0.44 | 0.33 |
| Stochastic Oscillator | 97.57 | 47.62 |
Tecnoglass Holdings Inc, formerly Tecnoglass Inc, is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.